

# **Global Human Microbiome Modulators Market: Focus on Non-Dairy Supplements, Drugs, Applications, 15 Countries Data, Pipeline Product Mapping, and Competitive Landscape – Analysis and Forecast, 2018-2023**

<https://marketpublishers.com/r/G3948733CFDFEN.html>

Date: December 2018

Pages: 275

Price: US\$ 5,000.00 (Single User License)

ID: G3948733CFDFEN

## **Abstracts**

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

In the era of precision medicine, the healthcare industry is focused on the development of advanced therapeutics to deliver improved patient care and enhance treatment outcome. The increasing prevalence of chronic disorders and an overall increased demand for preventive medication with minimal/no side-effect are promoting the growth of the human microbiome modulators market. Thereby, the advent of precision medicine approach and development of individualized care regimes are improving quality of life of the patients and reducing economic, societal, and clinical burden.

Presently, product categories within the human microbiome modulators market include probiotics and creams, prebiotics and dietary supplements, and drugs. Till date, the healthcare industry has witnessed a number of successful products modulating the gut microbiome, addressing digestive health. However, successful research substantiating a more inclusive role of the microbiome in human health and diseases, including immune health, women's health, oral health, and other health applications such as skin health, have further drawn the attention of several pharmaceutical companies to venture into this lucrative market by either advancing their respective product portfolios or acquiring companies with immense potentials. Further, several players are now focusing on the development of drugs modulating the microbiome, which is anticipated to enhance the growth of the entire market.

The purpose of the study is to gain a holistic view of the global human microbiome modulators market in terms of various factors influencing the market, including regulatory reforms and technological advancements. The market has been segmented into 'products', 'applications', and 'regions'. The scope of this report is centered upon conducting a detailed study of the products allied with the human microbiome modulators market. In addition, the study also includes the exhaustive information on the unmet needs, perception on the new products, competitive landscape (including pipeline analysis), market share of leading manufacturers, growth potential of each product, application, and region, as well as other vital information with respect to human microbiome modulators market. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global human microbiome modulators market with the help of the key factors driving the market, the restraints, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter's Five Forces for a comprehensive understanding of the global human microbiome modulators market. Moreover, the study includes detailed product mapping, market estimation, and analysis of key trends in multiple geographical regions, growth of human microbiome modulators market in each region for different applications, and the key strategies and developments by the prominent human microbiome modulators manufacturers.

The answers to the following key questions can be derived from this report:

What are the major market drivers, challenges, and opportunities in the global human microbiome modulators market?

What are the underlying structures resulting in the emerging trends within the human microbiome modulators industry?

What was the market value of the leading segments and sub-segments of the global human microbiome modulators market in 2017?

How will each segment of the global human microbiome modulators market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2023?

What are the influencing factors that may affect the market share of the key players?

How will the industry evolve during the forecast period, 2018- 2023?

What are the key developmental strategies which are being implemented by the key players in order to sustain in the competitive market?

What are the key product types in human microbiome modulators market? What are the major benefits of each product type?

How has the market been segmented on the basis of application? Which application is dominating the global human microbiome modulators market and its reason?

Who are the key manufacturers in human microbiome modulators market and what are their contributions?

What is the status of each major human microbiome modulators manufacturer with respect to their pipeline?

What is the scope of each human microbiome modulators product in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?

What are the key regulatory implications in developed and developing regions for human microbiome modulators?

What is the growth potential of human microbiome modulators in each region, including North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World?

Which human microbiome modulators product type is having most promising

growth and in which application type?

The key manufacturers who have been contributing significantly to the human microbiome modulators market include Sanofi S.A., The Procter and Gamble Company, Bayer AG, Koninklijke DSM N.V., E. I. du Pont de Nemours and Company, Yakult Honsha Co., Ltd., BioGaia AB, Probi AB, Chr. Hansen Holding A/S, Ingredion Incorporated, and Immuron Ltd., among others.

## Contents

### EXECUTIVE SUMMARY

### 1 MARKET OVERVIEW

- 1.1 Classification of Human Microbiome Modulators
- 1.2 Historical Perspective of Human Microbiome Modulators
- 1.3 The Human Microbiome Project (2007-2016)
- 1.4 Impact of Microbiome on Human Physiology
- 1.5 Global Footprint
- 1.6 Human Microbiome Modulators: Future Potential

### 2 MARKET DYNAMICS

- 2.1 Overview
- 2.2 Iceberg Analysis
- 2.3 Market Drivers
  - 2.3.1 Rising Geriatric Population
  - 2.3.2 Increasing Incidence of Lifestyle-related Diseases
  - 2.3.3 Gradual Demand for Preventive Medication with Minimal/No Side-Effects
  - 2.3.4 Limited Success Rate of Drugs Targeting Specific Diseases
- 2.4 Market Restraints
  - 2.4.1 Insufficient Application-Based Research Hindering Market Pull
  - 2.4.2 Lack of Awareness Regarding the Usage of Probiotics and Prebiotics
  - 2.4.3 Non-Harmonized Government Regulations on Probiotics and Prebiotics
- 2.5 Market Opportunities
  - 2.5.1 Massive Scope for Phenomenal Profits through Venturous Investments
  - 2.5.2 Integrative Industry-Academia Collaboration
  - 2.5.3 Rise of Next-Generation Probiotics
  - 2.5.4 Novel Diagnostic Applications

### 3 COMPETITIVE LANDSCAPE

- 3.1 Key Strategies and Developments
  - 3.1.1 Joint Ventures, Collaborations, and Partnerships
  - 3.1.2 Fundings and Business Expansion Activities
  - 3.1.3 Product Launch
  - 3.1.4 Mergers and Acquisitions

- 3.1.5 Product Approvals
- 3.2 Market Share Analysis
- 3.3 Growth Share Analysis
  - 3.3.1 Growth Share Analysis (by Application)
  - 3.3.2 Growth Share Analysis (by Company)
  - 3.3.3 Growth Share Analysis (by Country)
- 3.4 Industry Attractiveness
  - 3.4.1 Bargaining Power of Suppliers
  - 3.4.2 Bargaining Power of Buyer
  - 3.4.3 Threat of New Entrants
  - 3.4.4 Threat of Substitute Products
  - 3.4.5 Intensity of Competitive Rivalry
- 3.5 Product Pipeline Analysis

## **4 REGULATORY FRAMEWORK**

- 4.1 Legal Requirements and Framework in the U.S.
  - 4.1.1 For Probiotics
  - 4.1.2 For Prebiotics/Dietary Fibers
  - 4.1.3 For Live Biotherapeutic Products (LBPs)
- 4.2 Legal Requirements and Framework in Europe
- 4.3 Legal Requirements and Framework in Asia-Pacific
  - 4.3.1 Japan
  - 4.3.2 China
- 4.4 Global Microbiome Consortia

## **5 GLOBAL HUMAN MICROBIOME MODULATORS MARKET (BY PRODUCT)**

- 5.1 Overview
- 5.2 Probiotics and Creams
- 5.3 Prebiotics and Dietary Supplements
- 5.4 Drugs

## **6 GLOBAL HUMAN MICROBIOME MODULATORS MARKET (BY APPLICATION)**

- 6.1 Overview
- 6.2 Digestive Health
- 6.3 Immune Health
- 6.4 Women's Health

6.5 Oral Health

6.6 Others

## **7 GLOBAL HUMAN MICROBIOME MODULATORS MARKET (BY REGION)**

7.1 Analysis of Growth Potential of Different Countries: Global Human Microbiome Modulators Market

7.2 North America

7.2.1 The U.S.

7.2.2 Canada

7.3 Europe

7.3.1 Italy

7.3.2 Russia

7.3.3 France

7.3.4 Poland

7.3.5 Germany

7.3.6 The U.K.

7.3.7 Rest-of-Europe

7.4 Asia-Pacific

7.4.1 Japan

7.4.2 Australia

7.4.3 South Korea

7.4.4 China

7.4.5 India

7.4.6 Rest-of-Asia-Pacific

7.5 Latin America

7.5.1 Brazil

7.5.2 Mexico

7.5.3 Rest-of-Latin America

7.6 Rest-of-the-World

## **8 COMPANY PROFILES**

8.1 Overview

8.2 Bayer AG

8.2.1 Company Overview

8.2.2 Role of Bayer AG in the Human Microbiome Modulators Market

8.2.3 Financials

8.2.4 Key Insights about Financial Health of the Company

- 8.2.5 Global Presence
- 8.2.6 SWOT Analysis
- 8.3 BioGaia AB
  - 8.3.1 Company Overview
  - 8.3.2 Role of BioGaia AB in the Human Microbiome Modulators Market
  - 8.3.3 Financials
  - 8.3.4 Key Insights about Financial Health of the Company
  - 8.3.5 Global Presence
  - 8.3.6 SWOT Analysis
- 8.4 Chr. Hansen Holding A/S
  - 8.4.1 Company Overview
  - 8.4.2 Role of Chr. Hansen Holding A/S in the Human Microbiome Modulators Market
  - 8.4.3 Financials
  - 8.4.4 Key Insights about Financial Health of the Company
  - 8.4.5 Global Presence
  - 8.4.6 SWOT Analysis
- 8.5 DowDuPont Inc.
  - 8.5.1 Company Overview
  - 8.5.2 Role of DowDuPont Inc. in the Human Microbiome Modulators Market
  - 8.5.3 Financials
  - 8.5.4 Key Insights about Financial Health of the Company
  - 8.5.5 Global Presence
  - 8.5.6 SWOT Analysis
- 8.6 Garden of Life, LLC.
  - 8.6.1 Company Overview
  - 8.6.2 Role of Garden of Life, LLC. in Human Microbiome Modulators Market
  - 8.6.3 SWOT Analysis
- 8.7 Ingredion Incorporated
  - 8.7.1 Company Overview
  - 8.7.2 Role of Ingredion Incorporated in Human Microbiome Modulators Market
  - 8.7.3 Financials
  - 8.7.4 Key Insights about Financial Health of the Company
  - 8.7.5 Global Presence
  - 8.7.6 SWOT Analysis
- 8.8 ISOThrive LLC
  - 8.8.1 Company Overview
  - 8.8.2 Role of ISOThrive LLC in the Human Microbiome Modulators Market
  - 8.8.3 SWOT Analysis
- 8.9 Jarrow Formulas, Inc.



- 8.9.1 Company Overview
- 8.9.2 Role of Jarrow Formulas, Inc. in Human Microbiome Modulators Market
- 8.9.3 SWOT Analysis
- 8.10 Koninklijke DSM N.V.
  - 8.10.1 Company Overview
  - 8.10.2 Role of Koninklijke DSM N.V. in the Human Microbiome Modulators Market
  - 8.10.3 Financials
  - 8.10.4 Key Insights about Financial Health of the Company
  - 8.10.5 Global Presence
  - 8.10.6 SWOT Analysis
- 8.11 Lallemand Inc.
  - 8.11.1 Company Overview
  - 8.11.2 Role of Lallemand Inc. in Human Microbiome Modulators Market
  - 8.11.3 SWOT Analysis
- 8.12 MicroBiome Therapeutics, LLC
  - 8.12.1 Company Overview
  - 8.12.2 Role of MicroBiome Therapeutics, LLC in Human Microbiome Modulators Market
  - 8.12.3 SWOT Analysis
- 8.13 Pharmavite LLC
  - 8.13.1 Company Overview
  - 8.13.2 Role of Pharmavite LLC in Human Microbiome Modulators Market
  - 8.13.3 SWOT Analysis
- 8.14 Probi AB
  - 8.14.1 Company Overview
  - 8.14.2 Role of Probi AB in the Human Microbiome Modulators Market
  - 8.14.3 Financials
  - 8.14.4 Key Insights about Financial Health of the Company
  - 8.14.5 Global Presence
  - 8.14.6 SWOT Analysis
- 8.15 Probiotics International Limited (ADM Protexin)
  - 8.15.1 Company Overview
  - 8.15.2 Role of ADM Protexin in Human Microbiome Modulators Market
  - 8.15.3 SWOT Analysis
- 8.16 Quorum Innovations, LLC
  - 8.16.1 Company Overview
  - 8.16.2 Role of Quorum Innovations, LLC in Human Microbiome Modulators Market
  - 8.16.3 SWOT Analysis
- 8.17 Sanofi S.A.

- 8.17.1 Company Overview
- 8.17.2 Role of Sanofi S.A. in Human Microbiome Modulators Market
- 8.17.3 Financials
  - 8.17.3.1 Key Insights about Financial Health of the Company
- 8.17.4 SWOT Analysis
- 8.18 The Procter and Gamble Company
  - 8.18.1 Company Overview
  - 8.18.2 Role of The Procter and Gamble Company in the Human Microbiome Modulators Market
  - 8.18.3 Financials
  - 8.18.4 Key Insights about Financial Health of the Company
  - 8.18.5 Global Presence
  - 8.18.6 SWOT Analysis
- 8.19 Yakult Honsha Co., Ltd.
  - 8.19.1 Company Overview
  - 8.19.2 Role of Yakult Honsha Co., Ltd. in Human Microbiome Modulators Market
  - 8.19.3 Financials
  - 8.19.4 Key Insights about Financial Health of the Company
  - 8.19.5 Global Presence
  - 8.19.6 SWOT Analysis

## **9 RESEARCH SCOPE AND METHODOLOGY**

- 9.1 Report Scope
- 9.2 Human Microbiome Modulators Market: Research Methodology

## List Of Tables

### LIST OF TABLES

Table 2.1 Impact Analysis of Market Drivers

Table 2.2 Impact Analysis of Market Restraints

Table 3.1 R&D Expenditure of Major Human Microbiome Therapeutic Companies (as of FY2017)

Table 4.1 Global Microbiome Consortiums and Their Participants

Table 6.1 Documented Microbial Associations with Disease Status

## List Of Figures

### LIST OF FIGURES

Figure 1 Antibiotic Resistance (%) in OECD Countries, 2014

Figure 2 Global Value of Precision Medicine Within Healthcare, 2016 and 2020

Figure 3 Impact Analysis of Market Drivers and Market Restraints, 2018-2023

Figure 4 Global Human Microbiome Modulators Market Snapshot

Figure 5 Dominating Segments of Global Human Microbiome Modulators Market, 2017 and 2023

Figure 6 Global Human Microbiome Modulators Market (by Products), 2017 and 2023

Figure 7 Global Human Microbiome Modulators Market (by Application), 2017 and 2023

Figure 8 Global Human Microbiome Modulator Market (by Region), 2017 and 2023

Figure 9 Pipeline Analysis

Figure 10 Vital Strategies Incorporated by Key Players in the Global Human Microbiome Modulators Market

Figure 11 Market Statistics

Figure 12 Market Share Analysis for the Global Human Microbiome Modulators Market, 2017

Figure 1.1 Classification of Human Microbiome Modulators

Figure 1.2 Evolution of Human Microbiome Modulators

Figure 1.3 Significant Milestones from the HMP (Phase 1)

Figure 1.4 Global Human Microbiome Modulators Market, 2017-2023

Figure 2.1 Iceberg Analysis

Figure 2.2 Projected Global Geriatric Population (in billion), 1900-2100

Figure 2.3 Global Deaths Per Year By Cause (WHO), 2016

Figure 2.4 Average Healthcare Expenditure (by OECD Countries), 2015

Figure 3.1 Share of Key Developments and Strategies, January 2014-August 2018

Figure 3.2 Agreement, Collaboration, and Partnership Share (by Companies), January 2014-August 2018

Figure 3.3 Funding and Expansion Activities Share (by Companies), January 2014-August 2018

Figure 3.4 Product Launches Share (by Companies), January 2014-August 2018

Figure 3.5 Merger and Acquisition Share (by Companies), January 2014-August 2018

Figure 3.6 Product Approval Share (by Companies), January 2014-August 2018

Figure 3.7 Market Share Analysis for the Global Human Microbiome Modulators Market, 2016

Figure 3.8 Market Share Analysis for Global Human Microbiome Modulators Market, 2017

Figure 3.9 Growth Share Matrix for Global Human Microbiome Modulators Market (by Application), 2017

Figure 3.10 Growth Share Matrix for Global Human Microbiome Modulators Market (by Company), 2017

Figure 3.11 Growth Share Matrix for Global Human Microbiome Modulators Market (by Country), 2017

Figure 3.12 Industry Attractiveness (Porter's Five Forces Analysis)

Figure 3.13 Bargaining Power of Suppliers: Overall Impact

Figure 3.14 Bargaining Power of Buyers: Overall Impact

Figure 3.15 Threat of New Entrants: Overall Impact

Figure 3.16 Threat of Substitute Products: Overall Impact

Figure 3.17 Intensity of Competitive Rivalry: Overall Impact

Figure 3.18 Pipeline Analysis

Figure 3.19 Distribution of Pipeline Products According to Their Development Stage

Figure 4.1 Guidelines for the Evaluation of Probiotics for Food Use

Figure 4.2 Guidelines for the Chemistry, Manufacturing, and Control of LBPs by the FDA, 2016

Figure 4.3 Guidelines on the Scientific Requirements for Health Claims by the EFSA (2015)

Figure 4.4 Guidelines by the CFDA for Approval of Health Foods

Figure 5.1 Human Microbiome Modulators Market (by Product)

Figure 5.2 Global Human Microbiome Modulators Market (by Product), 2017 and 2023

Figure 5.3 Mechanism of Action of Probiotic in the Gut Microbiome

Figure 5.4 Global Human Microbiome Modulators Market (by Probiotics and Creams), 2017-2023

Figure 5.5 Effects of Prebiotics in Human Body

Figure 5.6 Global Human Microbiome Modulators Market (by Prebiotics and Dietary Supplements), 2017-2023

Figure 5.7 Mechanisms of Action of Human Microbiome Therapeutic Drugs

Figure 5.8 Number of Drugs in Active Development, 2011-2017

Figure 5.9 Global Human Microbiome Modulators Market (by Drugs), 2017-2023

Figure 6.1 Global Human Microbiome Modulators Market (by Application), 2017 and 2023

Figure 6.2 Global Human Microbiome Modulators Market (by Digestive Health), 2017-2023

Figure 6.3 Total Market Size for Digestive Health-related Modulators (2017-2023)

Figure 6.4 Interdepending Regulators of the Immune System

Figure 6.5 Global Human Microbiome Modulators Market (by Immune Health), 2017-2023

Figure 6.6 Total Market Size for Immune Health-related Modulators (2017-2023)

Figure 6.7 Inter-related Factors Governing Women's Health

Figure 6.8 Global Human Microbiome Modulators Market (by Women's Health), 2017-2023

Figure 6.9 Total Market Size for Women's Health-related Modulators (2017-2023)

Figure 6.10 Ecological Shifts in the Oral Microbiome Causing a Diseased Oral Cavity

Figure 6.11 Global Human Microbiome Modulators Market (by Oral Health), 2017-2023

Figure 6.12 Total Market Size for Oral Health-related Modulators (2017-2023)

Figure 6.13 Global Human Microbiome Modulators Market (by Other Health Applications), 2017-2023

Figure 6.14 Total Market Size for Other Health-related Modulators, 2017-2023

Figure 7.1 Global Human Microbiome Modulators Market Scenario, 2017 and 2023

Figure 7.2 Global Human Microbiome Modulators (by Region), 2017-2023

Figure 7.3 Analysis of Growth Potential (by Countries)

Figure 7.4 North America: Human Microbiome Modulators Market, 2017-2023

Figure 7.5 North America: Market Dynamics

Figure 7.6 North America: Human Microbiome Modulators Market (by Country), 2017 and 2023

Figure 7.7 The U.S.: Human Microbiome Modulators Market, 2017-2023

Figure 7.8 Canada: Human Microbiome Modulators Market, 2017-2023

Figure 7.9 Europe: Human Microbiome Modulators Market, 2017-2023

Figure 7.10 Europe: Market Dynamics

Figure 7.11 Europe: Human Microbiome Modulators Market (by Country), 2017 and 2023

Figure 7.12 Italy: Human Microbiome Modulators Market, 2017-2023

Figure 7.13 Russia: Human Microbiome Modulators Market, 2017-2023

Figure 7.14 France: Human Microbiome Modulators Market, 2017-2023

Figure 7.15 Poland: Human Microbiome Modulators Market, 2017-2023

Figure 7.16 Germany: Human Microbiome Modulators Market, 2017-2023

Figure 7.17 The U.K.: Human Microbiome Modulators Market, 2017-2023

Figure 7.18 Rest-of-Europe: Human Microbiome Modulators Market, 2017-2023

Figure 7.19 Asia-Pacific: Human Microbiome Modulators Market, 2017-2023

Figure 7.20 Asia-Pacific: Market Dynamics

Figure 7.21 Asia Pacific: Human Microbiome Modulators Market (by Country), 2017 and 2023

Figure 7.22 Japan: Human Microbiome Modulators Market, 2017-2023

Figure 7.23 Australia: Human Microbiome Modulators Market, 2017-2023

Figure 7.24 South Korea: Human Microbiome Modulators Market, 2017-2023

Figure 7.25 China: Human Microbiome Modulators Market, 2017-2023

- Figure 7.26 India: Human Microbiome Modulators Market, 2017-2023
- Figure 7.27 Rest-of-Asia Pacific: Human Microbiome Modulators Market, 2017-2023
- Figure 7.28 Latin America: Human Microbiome Modulators Market, 2017-2023
- Figure 7.29 Latin America: Market Dynamics
- Figure 7.30 Latin America: Human Microbiome Modulators Market (by Country), 2017 and 2023
- Figure 7.31 Brazil: Human Microbiome Modulators Market, 2017-2023
- Figure 7.32 Mexico: Human Microbiome Modulators Market, 2017-2023
- Figure 7.33 Rest-of-Latin America: Human Microbiome Modulators Market, 2017-2023
- Figure 7.34 Rest-of-the-World: Human Microbiome Modulators Market, 2017-2023
- Figure 8.1 Total Number of Companies Profiled
- Figure 8.2 Bayer AG: Product Portfolio for Human Microbiome Modulators Market
- Figure 8.3 Bayer AG: Overall Financials, 2015-2017
- Figure 8.4 Bayer AG: Revenue (by Segment), 2015-2017
- Figure 8.5 Bayer AG: Revenue (by Region), 2015-2017
- Figure 8.6 Bayer AG: R&D Expenditure, 2015-2017
- Figure 8.7 Bayer AG: Global Presence, 2015-2017
- Figure 8.8 Bayer AG: SWOT Analysis
- Figure 8.9 BioGaia AB: Product Portfolio for Human Microbiome Modulators Market
- Figure 8.10 BioGaia AB: Overall Financials, 2015-2017
- Figure 8.11 BioGaia AB: Revenue (by Segment), 2015-2017
- Figure 8.12 BioGaia AB: Revenue (by Region), 2015-2017
- Figure 8.13 BioGaia AB: R&D Expenditure, 2015-2017
- Figure 8.14 BioGaia AB: Revenue Forecast, 2015-2020
- Figure 8.15 BioGaia AB: Global Presence, 2015-2017
- Figure 8.16 BioGaia AB: SWOT Analysis
- Figure 8.17 Chr. Hansen Holding A/S: Product Portfolio for Human Microbiome Modulators Market
- Figure 8.18 Chr. Hansen Holding A/S: Overall Financials, 2015-2017
- Figure 8.19 Chr. Hansen Holding A/S: Revenue (by Segment), 2015-2017
- Figure 8.20 Chr. Hansen Holding A/S: Revenue (by Region), 2015-2017
- Figure 8.21 Chr. Hansen Holding A/S: R&D Expenditure, 2015-2017
- Figure 8.22 Chr. Hansen Holding A/S: Revenue Forecast, 2015-2020
- Figure 8.23 Chr. Hansen Holding A/S: Global Presence, 2015-2017
- Figure 8.24 Chr. Hansen Holding A/S: SWOT Analysis
- Figure 8.25 DowDuPont Inc.: Product Portfolio for Human Microbiome Modulators Market
- Figure 8.26 DowDuPont Inc.: Overall Financials, 2015-2017
- Figure 8.27 DowDuPont Inc.: Revenue (by Segment), 2015-2017



- Figure 8.28 DowDuPont Inc.: Revenue (by Region), 2015-2017
- Figure 8.29 DowDuPont Inc.: R&D Expenditure, 2015-2017
- Figure 8.30 DowDuPont Inc.: Global Presence, 2015-2017
- Figure 8.31 DowDuPont Inc.: SWOT Analysis
- Figure 8.32 Garden of Life, LLC.: Overall Product Portfolio
- Figure 8.33 Garden of Life, LLC.: SWOT Analysis
- Figure 8.34 Ingredion Incorporated: Product Portfolio for Human Microbiome Modulators Market
- Figure 8.35 Ingredion Incorporated: Overall Financials, 2015-2017
- Figure 8.36 Ingredion Incorporated: Revenue (by Segment), 2015-2017
- Figure 8.37 Ingredion Incorporated: Revenue (by Region), 2015-2017
- Figure 8.38 Ingredion Incorporated: R&D Expenditure, 2015-2017
- Figure 8.39 Ingredion Incorporated: Revenue Forecast, 2015-2020
- Figure 8.40 Ingredion Incorporated: Global Presence, 2015-2017
- Figure 8.41 Ingredion Incorporated: SWOT Analysis
- Figure 8.42 ISOThrive LLC.: Overall Product Portfolio
- Figure 8.43 ISOThrive LLC: SWOT Analysis
- Figure 8.44 Jarrow Formulas, Inc.: Overall Product Portfolio
- Figure 8.45 Jarrow Formulas, Inc.: SWOT Analysis
- Figure 8.46 Koninklijke DSM N.V.: Product Portfolio for Human Microbiome Modulators Market
- Figure 8.47 Koninklijke DSM N.V.: Overall Financials, 2015-2017
- Figure 8.48 Koninklijke DSM N.V.: Revenue (by Segment), 2015-2017
- Figure 8.49 Koninklijke DSM N.V.: Revenue (by Region), 2015-2017
- Figure 8.50 Koninklijke DSM N.V.: R&D Expenditure, 2015-2017
- Figure 8.51 Koninklijke DSM N.V.: Global Presence, 2015-2017
- Figure 8.52 Koninklijke DSM N.V.: SWOT Analysis
- Figure 8.53 Lallemand Inc.: Overall Product Portfolio
- Figure 8.54 Lallemand Inc.: SWOT Analysis
- Figure 8.55 MicroBiome Therapeutics, LLC: Overall Product Portfolio
- Figure 8.56 MicroBiome Therapeutics, LLC: SWOT Analysis
- Figure 8.57 Pharmavite LLC: Overall Product Portfolio
- Figure 8.58 Pharmavite LLC: SWOT Analysis
- Figure 8.59 Probi AB: Product Portfolio for Human Microbiome Modulators Market
- Figure 8.60 Probi AB: Overall Financials, 2015-2017
- Figure 8.61 Probi AB: Revenue (by Segment), 2015-2017
- Figure 8.62 Probi AB: Revenue (by Region), 2015-2017
- Figure 8.63 Probi AB: R&D Expenditure, 2015-2017
- Figure 8.64 Probi AB: Revenue Forecast, 2015-2020



- Figure 8.65 Probi AB: Global Presence, 2015-2017
- Figure 8.66 Probi AB: SWOT Analysis
- Figure 8.67 ADM Protexin: Overall Product Portfolio
- Figure 8.68 ADM Protexin: SWOT Analysis
- Figure 8.69 Quorum Innovations, LLC: Overall Product Portfolio
- Figure 8.70 Quorum Innovations, LLC: SWOT Analysis
- Figure 8.71 Sanofi S.A.: Product Portfolio for Human Microbiome Modulators Market
- Figure 8.72 Sanofi S.A.: Overall Financials, 2015-2017
- Figure 8.73 Sanofi S.A.: Revenue (by Segment), 2015-2017
- Figure 8.74 Sanofi S.A.: Revenue (by Region), 2015-2017
- Figure 8.75 Sanofi S.A.: R&D Expenditure, 2015-2017
- Figure 8.76 Sanofi S.A.: Revenue Forecast, 2015-2020
- Figure 8.77 Sanofi S.A.: SWOT Analysis
- Figure 8.78 The Procter and Gamble Company: Product Portfolio for Human Microbiome Modulators Market
- Figure 8.79 The Procter and Gamble Company: Overall Financials, 2016-2018
- Figure 8.80 The Procter and Gamble Company: Revenue (by Segment), 2016-2018
- Figure 8.81 The Procter and Gamble Company: Revenue (by Region), 2016-2018
- Figure 8.82 Procter and Gamble Company: R&D Expenditure, 2016-2018
- Figure 8.83 The Procter and Gamble Company: Global Presence, 2016-2018
- Figure 8.84 The Procter and Gamble Company: SWOT Analysis
- Figure 8.85 Yakult Honsha Co., Ltd.: Product Portfolio for Human Microbiome Modulators Market
- Figure 8.86 Yakult Honsha Co., Ltd.: Overall Financials, 2015-2017
- Figure 8.87 Yakult Honsha Co., Ltd.: Revenue (by Segment), 2015-2017
- Figure 8.88 Yakult Honsha Co., Ltd.: Revenue (by Region), 2015-2017
- Figure 8.89 Yakult Honsha Co., Ltd.: R&D Expenditure, 2015-2017
- Figure 8.90 Yakult Honsha Co., Ltd.: Global Presence, 2015-2017
- Figure 8.91 Yakult Honsha Co., Ltd.: SWOT Analysis
- Figure 9.1 Global Human Microbiome Modulators Market Segmentation
- Figure 9.2 Global Human Microbiome Modulators Market Research Methodology
- Figure 9.3 Primary Research
- Figure 9.4 Secondary Research
- Figure 9.5 Data Triangulation
- Figure 9.6 Bottom-up Approach (Segment-wise Analysis)
- Figure 9.7 Top-down Approach (Segment-wise Analysis)
- Figure 9.8 Assumptions and Limitations
- Figure 9.9 Considered Factors for Data Prediction and Modeling

## I would like to order

Product name: Global Human Microbiome Modulators Market: Focus on Non-Dairy Supplements, Drugs, Applications, 15 Countries Data, Pipeline Product Mapping, and Competitive Landscape – Analysis and Forecast, 2018-2023

Product link: <https://marketpublishers.com/r/G3948733CFDFEN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3948733CFDFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970